跳至主要内容
临床试验/NCT07670234
NCT07670234招募中不适用

Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software

Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2025年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
1
主要终点
Prevalence of Dietary Supplement Use and Tolerance

研究概览

简要总结

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.

The main questions it aims to answer :

  • What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
  • Are there any potential drug interactions between dietary supplements and anticancer medications?

Participants will:

  • Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
  • Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
  • Report any perceived adverse effects related to dietary supplement use to assess tolerance.
  • Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
  • Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
  • Adult patients : >=18

排除标准

  • Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
  • Failure or refusal to provide written informed consent.

结局指标

主要结局

Prevalence of Dietary Supplement Use and Tolerance

时间窗: At enrollment

Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.

Potential Drug-Supplement Interactions

时间窗: At enrollment or single study visit

Assessment of potential interactions between dietary supplements and anticancer medications

次要结局

  • Potential Drug-Supplement Interactions Assessed by Artificial Intelligence(At enrollment or Single study visit)

研究者

发起方
Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sihame Lkhoyaali

Professor of Medical Oncology

Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

研究点 (1)

Loading locations...

相似试验